Overall, circSOBP inhibits BCa tumorigenesis and metastasis by a novel miR-200a-3p/PTEN axis, which makes it an excellent biomarker and therapeutic target for treating BCa.
circSOBP Inhibits Bladder Cancer Proliferation and Metastasis by Regulating the miR-200a-3p/PTEN Axis and Participating in the Immune Response.